Novel Antischistosomal Agent

Abstract

An object of the present invention is to provide a novel antischistosomal agent, and more specifically, to provide a novel drug capable of inhibiting a growth of schistosomes in vivo to prevent development of liver dysfunction due to eggs of the schistosomes in the case of infection with the schistosomes. The novel antischistosomal agent includes as an active ingredient a peroxide derivative. Specifically, the novel antischistosomal agent includes as an active ingredient a peroxide derivative represented by the general formula (I): where C represents an alicyclic hydrocarbon ring group which may be substituted, and n represents an integer of 1 to 6.

1 . A novel antischistosomal agent, comprising as an active ingredient a peroxide derivative represented by the general formula (I): 
       
         
           
           
               
               
           
         
         wherein C represents a monocyclic alicyclic hydrocarbon group having 3 to 12 carbon atoms or an adamantylidene group, which may have a linear or branched lower alkyl group having 1 to 6 carbon atoms as a substituent, and n represents an integer of 1 to 6. 
       
     
     
         2 . (canceled) 
     
     
         3 . A novel antischistosomal agent according to  claim 1 , wherein the peroxide derivative is a compound represented by the general formula (I) wherein C represents a 4-tert-butylcyclohexylidene, cyclododecylidene, or adamantylidene group, and n represents an integer of 1 to 4. 
     
     
         4 . A novel antischistosomal agent according to  claim 1 , wherein the peroxide derivative is a compound represented by the following formula (II): 
       
         
           
           
               
               
           
         
       
     
     
         5 . A novel antischistosomal agent, comprising as an active ingredient a peroxide derivative represented by the general formula (I), which is used in such a manner that the peroxide derivative is administered two or four times a week at a dosage of 1 to 1,000 mg on any one or a plurality of weeks selected from Weeks 2 to 7 after infection with schistosomes: 
       
         
           
           
               
               
           
         
         wherein C represents a monocyclic alicyclic hydrocarbon group having 3 to 12 carbon atoms or an adamantylidene group, which may have a linear or branched lower alkyl group having 1 to 6 carbon atoms as a substituent, and n represents an integer of 1 to 6. 
       
     
     
         6 . A novel antischistosomal agent according to  claim 5 , which is used in such a manner that the peroxide derivative is administered two or four times a week at a dosage of 1 to 1,000 mg on Weeks 2 and/or 5 after infection with schistosomes. 
     
     
         7 . A novel antischistosomal agent according to  claim 5 , which is used in such a manner that the peroxide derivative is administered two or four times at a dosage of 1 to 1,000 mg on Week 5 after infection with schistosomes. 
     
     
         8 . A novel antischistosomal agent according to  claim 5 , wherein the peroxide derivative comprises a peroxide derivative represented by the general formula (I), wherein C represents a 4-tert-butylcyclohexylidene, cyclododecylidene, or adamantylidene group, and n represents an integer of 1 to 4. 
     
     
         9 . A novel antischistosomal agent according to  claim 5 , wherein the peroxide derivative is a compound represented by the following formula (II): 
       
         
           
           
               
               
           
         
       
     
     
         10 . A novel antischistosomal agent according to  claim 1 , wherein the novel antischistosomal agent further comprises olive oil. 
     
     
         11 . A novel antischistosomal agent according to  claim 10 , wherein the novel antischistosomal agent comprises the peroxide derivative in a blending ratio of 120 mg with respect to 2 ml of the olive oil.